AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00360828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continued Irinotecan Hydrochloride (HCI) Treatment
Description: For patients responding to treatment, therapy could have continued beyond 18 cycles.
Study NCT00991666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood flow measurement
Description: Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
Study NCT00991666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood flow measurement
Description: Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
Study NCT01848587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT01848587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT03070379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical lidocaine pharyngeal anesthesia
Description: Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
Study NCT03821298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Hand Therapy
Description: 8 sessions 2 times a week for 4 weeks
Study NCT01883414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy™
Description: All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
Study NCT00555750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3mg tablet, by mouth nightly 30 min before bed, for two months
Study NCT00555750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
Study NCT02652416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: oral administration
Study NCT03160534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative exercise
Description: Each intervention session contains a stretching part and aerobic training
Study NCT02984189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
Study NCT02984189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
Study NCT02984189 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
Study NCT00569296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRBi-armed autologous activated T cells
Description: Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
Study NCT00569296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
Study NCT03340662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: CYP3A Inhibitor
Study NCT00569296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: 250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
Study NCT03340662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: CYP1A2 Inhibitor
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 1mg/kg
Description: single-dose:1mg/kg
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 3mg/kg
Description: single-dose: 3mg/kg
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 10mg/kg
Description: single-dose:10mg/kg
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 1mg/kg, q2w*6
Description: multiple dosing: 1mg/kg, q2w\*6
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 3mg/kg, q2w*6
Description: multiple dosing: 3mg/kg, q2w\*6
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 10mg/kg, , q2w*6
Description: multiple dosing: 10mg/kg, , q2w\*6
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 280mg, q3w
Description: multiple dosing: 280mg, q3w
Study NCT03374007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 3mg/kg, q2w
Description: multiple dosing: 3mg/kg, q2w
Study NCT03123276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: humanized IgG4 PD-1 blocking antibody
Study NCT03123276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
Study NCT02758639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wonders & Worries Psychosocial Intervention
Description: Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
Study NCT02652416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02652416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT03345524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Buddy System
Description: 2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed
Study NCT02758639 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wonders & Worries Psychosocial Intervention
Description: Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
Study NCT03345524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)
Study NCT03022500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab + tremelimumab
Description: Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study NCT01940393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Drug administration
Study NCT01940393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Drug Administration
Study NCT05468801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Homeopathic Remedy
Description: An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
Study NCT05468801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus Standard Pharmacologic Treatment
Study NCT03482115 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET examination with radiopharmaceutical drug [18F] DPA-714
Description: Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
Study NCT03482115 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET examination with radiopharmaceutical drug [18F] DPA-714
Description: Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
Study NCT03482115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
Study NCT03482115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI examination
Description: MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
Study NCT03482115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
Study NCT03482115 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
Study NCT03414476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair follicles sampling
Description: The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
Study NCT03870165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
Study NCT03870165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
Study NCT03870165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salmon
Description: Participants will ingest salmon immediately after resistance exercise
Study NCT03870165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated amino acids and fatty acids
Description: Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
Study NCT02089607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal Aortic Aneurysm Arm
Description: The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
Study NCT02089607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic Arch Aneurysm Arm
Description: The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
Study NCT00805467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
Study NCT03305627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short PAP
Description: Perioperative antibiotic prophylaxis for 24h
Study NCT03305627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extended PAP
Description: Perioperative antibiotic prophylaxis for >48h
Study NCT00489255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigan®
Description: Oral capsule, 300mg three times daily
Study NCT00489255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule, three times daily
Study NCT01940393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Drug administration
Study NCT01940393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebastine
Description: Drug administration
Study NCT05159024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CRP, PCT, and WBCs trajectories
Description: the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
Study NCT02085447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAE-L
Description: Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
Study NCT02490644 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling 5ml
Study NCT02741414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of H pylori culture based on gram staining and enzyme activity testing
Description: This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
Study NCT02741414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole
Description: The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
Study NCT02741414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing
Description: The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
Study NCT02387411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval exercise training
Description: High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]
Study NCT02387411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise training
Description: High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
Study NCT01654016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detralex
Description: Detralex 500 mg twice daily for three month prior to surgery
Study NCT01810757 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard planning radiotherapy
Description: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
Study NCT01810757 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive planning radiotherapy
Description: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
Study NCT04457037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells
Study NCT00972595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron clinical trial formulation
Description: Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
Study NCT03340662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: CYP3A Inducer
Study NCT03230448 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
Study NCT03342261 — intervention group
Intervention type: DRUG
Intervention: DAA treatment
Description: Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
Study NCT02052167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methotrexate prefilled pen
Study NCT01940393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: Drug administration
Study NCT02066129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 44 mcg
Description: Fluticasone is an inhaled corticosteroid
Study NCT00972595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron marketed formulation
Description: Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.